Substituted tricyclic compounds as FGFR inhibitors
申请人:Incyte Corporation
公开号:US11053246B2
公开(公告)日:2021-07-06
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
申请人:Incyte Holdings Corporation
公开号:EP2861595B9
公开(公告)日:2017-06-21
US9611267B2
申请人:——
公开号:US9611267B2
公开(公告)日:2017-04-04
[EN] SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR
申请人:INCYTE CORP
公开号:WO2014007951A2
公开(公告)日:2014-01-09
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.